Nabriva Therapeutics AG Current Ratio 2015-2021 | NBRV

Nabriva Therapeutics AG current ratio from 2015 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Nabriva Therapeutics AG Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.10B $0.02B 4.93
2021-03-31 $0.08B $0.02B 4.29
2020-12-31 $0.06B $0.02B 3.09
2020-09-30 $0.05B $0.01B 4.95
2020-06-30 $0.06B $0.01B 5.68
2020-03-31 $0.04B $0.01B 3.19
2019-12-31 $0.09B $0.02B 5.48
2019-09-30 $0.09B $0.02B 5.81
2019-06-30 $0.08B $0.01B 5.67
2019-03-31 $0.10B $0.02B 5.55
2018-12-31 $0.11B $0.02B 6.11
2018-09-30 $0.11B $0.02B 7.35
2018-06-30 $0.09B $0.01B 7.52
2018-03-31 $0.10B $0.01B 8.65
2017-12-31 $0.09B $0.01B 7.08
2017-09-30 $0.12B $0.02B 7.22
2017-06-30 $0.06B $0.02B 3.77
2017-03-31 $0.08B $0.02B 4.82
2016-12-31 $0.09B $0.02B 5.71
2016-09-30 $0.08B $0.01B 5.87
2016-06-30 $0.09B $0.01B 7.87
2016-03-31 $0.11B $0.01B 7.71
2015-12-31 $0.12B $0.01B 13.03
2015-09-30 $0.13B $0.01B 11.35
2015-06-30 $0.00B 0.00
2015-03-31 $0.01B $0.05B 0.12
2014-12-31 $0.00B $0.04B 0.12
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.587B $0.005B
Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics' medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics' lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP).
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71